Multiple Myeloma

Ixazomib Maintenance After ASCT Improves Progression-Free, Overall Survival in Multiple Myeloma

Ixazomib Maintenance After ASCT Improves Progression-Free, Overall Survival in Multiple Myeloma

By

An international study sought to determine if ixazomib maintenance after autologous stem cell transplantation would improve progression-free survival and overall survival.

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

By

Continuous therapy appears to be the preferred treatment modality in newly diagnosed patients with multiple myeloma (MM).

Depth of Response Translates Into Real-World Benefit in Multiple Myeloma

Depth of Response Translates Into Real-World Benefit in Multiple Myeloma

By

Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.

Study Determines Preferred Attributes of PI Combination Therapies for R/R Multiple Myeloma

Study Determines Preferred Attributes of PI Combination Therapies for R/R Multiple Myeloma

By

In this study, researchers sought to determine the preferred treatment attributes of patients with RRMM, and which they are willing to let go in trade-offs.

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

By

Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.

Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value

Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value

By

Stringent CR criteria may not predict clinical outcomes for patients with multiple myeloma.

Perspectives on Use of Sensored Medication Devices From Patients With Multiple Myeloma

Perspectives on Use of Sensored Medication Devices From Patients With Multiple Myeloma

By

Researchers conducted a study to gauge the potential acceptance of sensored medication devices among patients with multiple myeloma.

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

By

A snapshot of an international Commission's report on the issues inherent with adverse event reports of hematologic malingnancies in clinical trials.

Prior Bortezomib Lowers Incidence of Lenalidomide-Induced Skin Toxicity in Multiple Myeloma

Prior Bortezomib Lowers Incidence of Lenalidomide-Induced Skin Toxicity in Multiple Myeloma

By

A study presented at ESMO 2018 demonstrated that incidence of skin toxicity in patients with multiple myeloma undergoing lenalidomide therapy was lower in those who received prior bortezomib.

Lenalidomide Maintenance Therapy May Be Best Treatment for Newly Diagnosed Multiple Myeloma

Lenalidomide Maintenance Therapy May Be Best Treatment for Newly Diagnosed Multiple Myeloma

By

A meta-analysis of 11 studies rated the efficacy of 8 maintenance therapies with lenalidomide in combination or as monotherapy for NDMM.

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

By

A retrospective follow-up study demonstrates that tandem autologous-allogeneic is safe for standard and high-risk multiple myeloma. However, benefits do not extend to patients with ultra-high-risk disease and those with disease progression after autologous HCT.

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

By

An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.

Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma

Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma

By

Researchers found that clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic in patients with multiple myeloma.

A Novel Formulation of Melphalan May Not Prevent Complications Post-ASCT in Multiple Myeloma

A Novel Formulation of Melphalan May Not Prevent Complications Post-ASCT in Multiple Myeloma

By

High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.

PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma

PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma

Reinforcing the immune system with a the PVX-410 vaccine may prevent or slow progression to multiple myeloma.

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

By

The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.

Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma

Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma

By

A prospective TLN cohort study demonstrated that trial eligibility is a strong predictor of progression-free and overall survival among patients with multiple myeloma.

No Negative Effects on HRQOL With Post-ASCT Maintenance Therapy for Multiple Myeloma

No Negative Effects on HRQOL With Post-ASCT Maintenance Therapy for Multiple Myeloma

By

Analysis of a cohort of patients with newly diagnosed multiple myeloma focused on the effect of post-ASCT maintenance therapy on health-related QOL and clinical outcomes.

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

By

In an analysis of 11 studies, researchers investigated whether the benefits of carfilzomib for multiple myeloma outweigh the cardiovascular risks. However, the researchers recommend careful monitoring and management of blood pressure and volume status as good clinical practice, regardless.

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

By

In this study, researchers investigated the effects of exercise on physical and psychological recovery after autoHSCT for multiple myeloma.

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

By

Three-drug regimen twice a week achieved good response and long-term outcomes in patients with newly diagnosed multiple myeloma; however, regimen has higher toxicity than once weekly dose.

First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma

First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma

By

The 18-month progression-free survival rate was 71.6% among patients treated with daratumumab plus VMP compared with 50.2% among patients treated with VMP alone.

Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years

Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years

By

A study presented at the 2018 ASCO Annual Meeting investigated the mortality risk for patients with multiple myeloma who develop VTE.

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

By

Investigators sought to determine the impact on quality of life for patients with relapsed/refractory multiple myeloma treated with PAN and BTZ+DEX.

RVD-Lite Has Comparable Efficacy, Improved Toxicity in Transplant-Ineligible MM

RVD-Lite Has Comparable Efficacy, Improved Toxicity in Transplant-Ineligible MM

By

In a single-arm phase 2 study, researchers explored the effectiveness of a modified lenalidomide, bortezomib, and dexamethasone (RVD-lite) regimen in transplant-ineligible patients with multiple myeloma.

Plateau-Oriented Induction Approach Inadequate in Transplant-Ineligible Multiple Myeloma

Plateau-Oriented Induction Approach Inadequate in Transplant-Ineligible Multiple Myeloma

By

In this phase 2 study, 38 patients with previously untreated multiple myeloma who were ineligible for autologous stem cell transplantation were treated with a bortezomib-containing induction regimen until plateau.

Firefighters in World Trade Center Attacks Have Increased Risk of Multiple Myeloma

Firefighters in World Trade Center Attacks Have Increased Risk of Multiple Myeloma

By

A case series demonstrates the prevalence of MGUS, a precursor condition to multiple myeloma, and subsequent development of MM in white firefighters who responded after the 9/11 attacks in New York City.

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

A study of 133 patients with multiple myeloma who experienced a first relapse compared the efficacy of long-term therapy lenalidomide alone vs with dexamethasone.

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

By

This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

By

In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs